<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01925885</url>
  </required_header>
  <id_info>
    <org_study_id>IU-1302010649</org_study_id>
    <nct_id>NCT01925885</nct_id>
  </id_info>
  <brief_title>Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)</brief_title>
  <acronym>FIRMAT-PAF</acronym>
  <official_title>Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Topera, Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Hypothesis: Focal Impulse and Rotor Modulation (FIRM) will substantially reduce or&#xD;
           eliminate clinical atrial fibrillation in subjects with accepted indications for&#xD;
           catheter ablation of paroxysmal AF, compared to standard pulmonary vein isolation.&#xD;
&#xD;
        -  Summary: This is a prospective randomized study to assess the safety and effectiveness&#xD;
           of FIRM procedures only, versus standard Pulmonary Vein Isolation (PVI) procedures for&#xD;
           the treatment of symptomatic paroxysmal atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 188 subjects will be enrolled-subjects will be equally (1:1) randomized between&#xD;
      those undergoing conventional atrial fibrillation ablation with confirmation of pulmonary&#xD;
      vein isolation (PVI) versus those actively treated with the FIRM procedure without PVI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    •Terminated: recruiting or enrolling participants has halted prematurely and will not resume;&#xD;
    participants are no longer being examined or treated&#xD;
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 23, 2015</completion_date>
  <primary_completion_date type="Actual">December 23, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Ablation Success for Paroxysmal Atrial Fibrillation</measure>
    <time_frame>1 week</time_frame>
    <description>the termination of spontaneous or induced atrial fibrillation by ablation at an atrial fibrillation source arrhythmia location&#xD;
the slowing of the mean atrial fibrillation rate at least by 10% by ablation at an atrial fibrillation source arrhythmia&#xD;
evaluate safety and effectiveness of the FIRM procedures for the treatment of paroxysmal atrial fibrillation&#xD;
freedom from major adverse events related to the procedure within 7 days of the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long Term Ablation Success for Paroxysmal Atrial Fibrillation</measure>
    <time_frame>1 year</time_frame>
    <description>freedom from atrial fibrillation recurrence (&gt;30sec) from 3-12 months&#xD;
freedom from major adverse events related to the procedure within one year of the procedure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1 year</time_frame>
    <description>EuroQOL Eq-5D scores pre-ablation will be compared to those post ablation at all points separately and together</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>PVI Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care arm-pulmonary vein isolation (PVI)-involving moving the ablation catheter from point to point in a continuous line to surround the the orifices of the pulmonary veins in order to eliminate electrical conduction between the veins and left atrium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FIRM Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FIRM ablation for paroxysmal atrial fibrillation at sites of rotors or focal impulse formation as designated by using the mapping algorithm of RhythmView</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVI Ablation</intervention_name>
    <description>PVI ablation for atrial fibrillation specifically targets areas in the left atrium in the area just outside the pulmonary veins to eliminate triggers of atrial fibrillation.</description>
    <arm_group_label>PVI Ablation</arm_group_label>
    <other_name>Ablation</other_name>
    <other_name>Atrial Fibrillation</other_name>
    <other_name>Arrhythmia</other_name>
    <other_name>Radiofrequency Ablation</other_name>
    <other_name>Mapping</other_name>
    <other_name>Pulmonary Veins</other_name>
    <other_name>Paroxysmal Atrial Fibrillation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FIRM Ablation</intervention_name>
    <description>Ablation for atrial fibrillation specifically targets areas in the left or right atrium to eliminate areas that maintain atrial fibrillation without isolating the pulmonary veins</description>
    <arm_group_label>FIRM Ablation</arm_group_label>
    <other_name>Ablation</other_name>
    <other_name>Atrial Fibrillation</other_name>
    <other_name>Arrhythmia</other_name>
    <other_name>Radiofrequency Ablation</other_name>
    <other_name>Mapping</other_name>
    <other_name>Rotors</other_name>
    <other_name>Pulmonary Veins</other_name>
    <other_name>Paroxysmal Atrial Fibrillation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Reported incidence of at least two (2) documented episodes of symptomatic paroxysmal&#xD;
             atrial fibrillation (AF) during the six months preceding trial entry (at least one&#xD;
             episode should be documented by rhythm strip or ECG).&#xD;
&#xD;
          -  Attempt of at least one Class I or III anti-arrhythmia drug with failure defined as&#xD;
             recurrence of symptomatic AF or adverse drug effect resulting in stopping the&#xD;
             medication (drug duration and dose will be documented).&#xD;
&#xD;
          -  Left atrial size &lt;55mm in largest dimension (typically atrial septum to carina of left&#xD;
             pulmonary veins) as measured and image documented by preoperative imaging (CT or MRI)&#xD;
&#xD;
          -  Anticoagulation therapy-Oral anticoagulation required (in the case of Warfarin,&#xD;
             therapeutic International Normalized Ratio (INR) for at least three weeks prior to&#xD;
             randomization) for those subjects who meet two or more of the following criteria:&#xD;
&#xD;
               1. Age 65 years or older&#xD;
&#xD;
               2. Diabetes&#xD;
&#xD;
               3. Prior stroke or transient ischemic attack&#xD;
&#xD;
               4. Congestive heart failure&#xD;
&#xD;
               5. Hypertension with systolic&gt;165 mm Hg&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction ≥ 40% (obtained within 12 months prior to the&#xD;
             procedure)&#xD;
&#xD;
          -  Sustained AF-if the patient is not experiencing spontaneous, sustained AF (&gt;10 min&#xD;
             uninterrupted), sustained AF may be induced by burst atrial pacing with or without&#xD;
             isoproterenol infusion in conventional clinical fashion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous catheter or surgical left atrial ablation&#xD;
&#xD;
          -  Structural heart disease of clinical significance including&#xD;
&#xD;
          -  Congenital heart disease where either the underlying abnormality or its correction&#xD;
             prohibits or increases the risk of ablation&#xD;
&#xD;
          -  Myocardial infarction (MI) within the past three (3) months&#xD;
&#xD;
          -  Any concomitant arrhythmia or therapy that could interfere with the interpretation of&#xD;
             the results from this study&#xD;
&#xD;
          -  Atrial Septal Defect closure device; Left Atrial Appendage closure device; prosthetic&#xD;
             mitral or tricuspid valve&#xD;
&#xD;
          -  Anaphylactic allergy to contrast media&#xD;
&#xD;
          -  Atrial fibrillation secondary to electrolyte imbalance&#xD;
&#xD;
               1. thyroid disease&#xD;
&#xD;
               2. reversible non-cardiac cause&#xD;
&#xD;
          -  Poor general health that, in the opinion of the investigator, will not allow the&#xD;
             patient to be a good study candidate (i.e. other disease processes, mental capacity,&#xD;
             etc.)&#xD;
&#xD;
          -  Reversible cause of atrial fibrillation (e.g. surgery, hyperthyroidism, pericarditis)&#xD;
&#xD;
          -  Contraindication to heparin and warfarin/other new oral anticoagulants (e.g.&#xD;
             dabigatran, rivaroxaban, apixaban [when available])&#xD;
&#xD;
          -  History of pulmonary embolus within one year of enrollment&#xD;
&#xD;
          -  Acute pulmonary edema&#xD;
&#xD;
          -  Atrial clot/thrombus on imaging such as on a trans-esophageal echocardiogram (TEE)&#xD;
             performed within 72 hours of the procedure if deemed appropriate by the investigator&#xD;
&#xD;
          -  Any history of a cerebrovascular disease-including stroke or Transient Ischemic Attack&#xD;
&#xD;
          -  Any anticipation of cardiac transplantation or other cardiac surgery within the next&#xD;
             365 days (12 months)&#xD;
&#xD;
          -  History of documented thromboembolic event within the past one year&#xD;
&#xD;
          -  Diagnosed atrial myxoma&#xD;
&#xD;
          -  Significant pulmonary disease&#xD;
&#xD;
          -  Acute illness or active systemic infection or sepsis&#xD;
&#xD;
          -  Any history of blood clotting abnormalities or bleeding tendencies unrelated to&#xD;
             supratherapeutic anticoagulation&#xD;
&#xD;
          -  Life expectancy &lt;365 days (12 months)&#xD;
&#xD;
          -  Any intracardiac thrombus, tumor. or other abnormality that precludes safe catheter&#xD;
             introduction or manipulation&#xD;
&#xD;
          -  Continuous AF episode lasting &gt;7 days immediately prior to the procedure without any&#xD;
             sinus rhythm&#xD;
&#xD;
          -  Patients who have previously undergone cardioversion are excluded from participation&#xD;
             in the study unless there is documentation that cardioversion has been performed&#xD;
             within 72 hours of episode onset&#xD;
&#xD;
          -  Amiodarone use in the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>August 5, 2013</study_first_submitted>
  <study_first_submitted_qc>August 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2013</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

